EC signs procurement contract for HIPRA COVID-19 vaccine

HERA, the European Commission’s Health Preparedness and Response Authority, has signed a joint procurement framework contract with the Spanish company HIPRA Human Health for the supply of its protein COVID-19 vaccine. 14 member states and countries are participating in this joint procurement, under which they can purchase up to 250 million doses.

As the number of cases is again on the rise in Europe, this agreement will make the HIPRA vaccine rapidly available to the participating countries, as soon as this vaccine has received a positive assessment by the European Medicines Agency.

Commissioner for Health and Food Safety, Stella Kyriakides, said: “With COVID-19 infections on the rise in Europe, we need to ensure maximum preparedness as we head into the autumn and winter months. The HIPRA vaccine adds yet another option to complement our broad vaccine portfolio for our Member States and citizens. An increase in vaccination and boosting is essential over the coming months. We are working tirelessly to make sure there are vaccines available for all. This is our European Health Union in action – preparing ahead and being ready to act.”